Rhonda L Bitting1,2, Michael Goodman3,4, Daniel J George5. 1. Durham VA Health Care System, Durham, NC, USA. Rhonda.bitting@duke.edu. 2. Duke Cancer Institute, Center for Prostate & Urologic Cancers, Duke University, Duke Box 103861, Durham, NC, 27710, USA. Rhonda.bitting@duke.edu. 3. Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC, USA. 4. W.G. (Bill) Hefner VA Medical Center, 1601 Brenner Ave, Salisbury, NC, 28144, USA. 5. Duke Cancer Institute, Center for Prostate & Urologic Cancers, Duke University, Duke Box 103861, Durham, NC, 27710, USA.
Abstract
PURPOSE OF REVIEW: In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Recent data suggests that, despite higher risk features, African Americans may respond better than Caucasians to systemic therapies for advanced prostate cancer. This improved response is not limited to one class of drugs but can be seen with androgen-pathway directed therapies, chemotherapy, bone-targeted therapy, and immunotherapy. The mechanisms for this are being further explored. African Americans may respond better to mCRPC treatments but validation in prospective clinical trials is needed.
PURPOSE OF REVIEW: In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Recent data suggests that, despite higher risk features, African Americans may respond better than Caucasians to systemic therapies for advanced prostate cancer. This improved response is not limited to one class of drugs but can be seen with androgen-pathway directed therapies, chemotherapy, bone-targeted therapy, and immunotherapy. The mechanisms for this are being further explored. African Americans may respond better to mCRPC treatments but validation in prospective clinical trials is needed.
Authors: Azariyas A Challa; Adam Christopher Calaway; Jennifer Cullen; Jorge Garcia; Nihar Desai; Neal L Weintraub; Anita Deswal; Shelby Kutty; Ajay Vallakati; Daniel Addison; Ragavendra Baliga; Courtney M Campbell; Avirup Guha Journal: Curr Treat Options Oncol Date: 2021-04-17